Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Fig. 2

CD4+CD25hiFoxP3+ Treg in peripheral blood before and after denileukin diftitox treatment. Peripheral blood mononuclear cells were isolated using density gradient centrifugation before and after patient received denileukin diftitox treatment versus no treatment. In the denileukin difitox arm, peripheral blood mononuclear cells were isolated at the time of consent (pre) and before the first vaccination (post). Tregs were first labeled with anti-CD4, anti-CD25, and anti-FoxP3 Abs from the Treg staining kit (Miltenyi Biotech, Inc.) and then analyzed using a MACSQuant analyzer. Paired student t-test was used to determine whether there was a statistical difference between the pre- and post-treatment samples in each cohort

Back to article page